DZCORT-18 is a premium pharmaceutical formulation from MK Healthcare, featuring Deflazacort (18mg), a potent third-generation corticosteroid. Classified as a glucocorticoid, DZCORT-18 is specifically engineered to provide superior anti-inflammatory and immunosuppressive effects with a more favorable safety profile compared to traditional steroids. This 18mg dosage is highly effective for managing moderate to severe inflammatory conditions, helping patients achieve faster recovery and long-term symptom control.

One of the primary clinical applications of DZCORT-18 is in the management of Duchenne Muscular Dystrophy (DMD). By reducing muscle inflammation and slowing down the degradation of muscle fibers, this medication plays a critical role in preserving muscle strength and improving mobility in both children and adults. Beyond neuromuscular care, it is widely prescribed for various autoimmune disorders, including rheumatoid arthritis, systemic lupus erythematosus, and severe allergic reactions, where it works by calming an overactive immune system.

The mechanism of action for DZCORT-18 involves inhibiting the release of chemical substances (cytokines) that trigger swelling, redness, and pain in the body. This makes it an essential tool in respiratory care for conditions like severe asthma and COPD, as well as in dermatology for managing chronic skin issues such as psoriasis and eczema. Because it is a systemic steroid, it provides comprehensive relief by stabilizing the body?s inflammatory response across multiple organ systems.

As a product of MK Healthcare, an ISO-GMP certified pharmaceutical company, DZCORT-18 is manufactured under the strictest quality protocols to ensure peak purity and bioavailability. Available in professional Alu-Alu packaging, it is a trusted choice for healthcare providers and PCD Pharma Franchise partners looking for reliable, high-efficacy steroidal treatments. To ensure safety and maximize therapeutic benefits, DZCORT-18 should always be taken under medical supervision with a strictly monitored dosage schedule.